HALFAN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Halfan, and what generic alternatives are available?
Halfan is a drug marketed by Glaxosmithkline and is included in one NDA.
The generic ingredient in HALFAN is halofantrine hydrochloride. Additional details are available on the halofantrine hydrochloride profile page.
Summary for HALFAN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 127 |
Patent Applications: | 233 |
Formulation / Manufacturing: | see details |
DailyMed Link: | HALFAN at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for HALFAN
US Patents and Regulatory Information for HALFAN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Glaxosmithkline | HALFAN | halofantrine hydrochloride | TABLET;ORAL | 020250-001 | Jul 24, 1992 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |